Design by Userking
Cardiovascular Health

Errors in Heart Risk Assessment: All-Too-Common, Easily Avoided

By Mark J. Tager, MD | Contributing Writer - Vol. 15, No. 2. Summer, 2014

Ancient Chinese philosophy defines two basic types of error: "Near-error," characterized by a myopic focus on what is closest at hand to the exclusion of the bigger picture and; "Far-error," an obsession with the horizon at the expense of what is in proximity.

Heart-Healthy Beverages: Think Before You Drink!

By Erik Goldman | Contributing Writer - Vol. 15, No. 1. Spring, 2014

When it comes to cardiovascular disease risk, what someone drinks can be as important as what he or she eats. But too often, clinicians overlook the beverage factor when making nutritional recommendations, says Steven Masley, MD, director of the Masley Optimal Health Center in St. Petersburg, FL, and author of the new book, "The 30-Day Heart Tune-Up (Hachette)."

"Odd Omegas" an Important Part of the Heart Health Picture

By John Otrompke | Contributing Writer

The Cleveland Clinic is beginning a series of clinical trials to assess the potential cardiovascular effects of Omega-7 fatty acids, a category of unsaturated fatty acids scientists are just beginning to understand.

Chelation Vindicated for CVD Risk Reduction in Diabetes

By Erik Goldman

New data from the NIH-funded Trial to Assess Chelation Therapy (TACT), has vindicated this controversial treatment as a method for preventing cardiovascular events in people with diabetes. The data show a clear 15% reduction in index events among treated patients.

When Questioning Clinical Dogma Is a Doctor’s Duty

By Erik Goldman | Contributing Writer - Vol. 15, No. 2. Summer, 2013

Twenty years ago, Dr. Stephen Sinatra was like most American cardiologists: firmly convinced that elevated cholesterol was the key driver of heart disease, and that thanks to statin drugs, he and his colleagues would soon be cutting the nation’s number one killer down to size.

Blood Pressure & CVD Risk: Are We Measuring the Right Thing?

By Peter Bottemanne | Contributing Writer - Vol. 15, No. 2. Summer, 2013

Despite our nation’s best effort to treat all forms of cardiovascular disease aggressively, we seem to be losing the struggle.

A New Angle on Nitric Oxide & CVD Prevention

By Erik Goldman - Vol. 14, No. 2. Summer, 2013
It's been more than two decades since nitric oxide was named "Molecule of the Year" by the journal, Science.

Pantethine a Safe Option for Patients “On the Cusp” of Cardiac Risk

By Erik Goldman - Vol. 13, No. 4. Winter, 2012

Pantethine, a derivative of vitamin B5, offers a safe option for improving lipid profiles and reducing cardiovascular risk beyond what can be obtained with a low-fat diet and lifestyle modification alone.

Endothelial Glycocalyx: A New Focus for Cardiovascular Risk Reduction

By Erik Goldman
The endothelial glycocalyx, a gel-like glycoprotein layer that coats the inner surface of the endothelium throughout the vascular tree, has become a new focus for reducing risk of atherosclerosis and cardiovascular events.

Drug Therapy Has Little Value In Early Stage Hypertension

By Erik Goldman
Amid the clamor over metanalyses suggesting that organic veggies are no more nutritious than conventional, and that omega-3's don't reverse heart disease, another important metanalysis got totally overlooked: the one showing that anti-hypertensive drugs are largely ineffective in people with Stage 1 hypertension.

^top

 

Copyright @ 2014 Holistic Primary Care. All Rights Reserved.